RHO methylation matters

References

• Glomset JA, Farnsworth CC. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu Rev Cell Biol 1994; 10:181 - 205
   PubMedGoogle Scholar
• Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 1996; 65:241 - 269
   PubMed Web of Science ®Google Scholar
• Casey PJ, Seabra MC. Protein prenyltransferases. J Biol Chem 1996; 271:5289 - 5292
   PubMed Web of Science ®Google Scholar
• Boyartchuk VL, Ashby MN, Rine J. Modulation of Ras and a-factor function by carboxyl-terminal proteolysis. Science 1997; 275:1796 - 1800
   PubMed Web of Science ®Google Scholar
• Dai Q, Choy E, Chiu V, Romano J, Slivka SR, Steitz SA, et al. Mammalian prenylcysteine carboxyl methyltransferase is in the endoplasmic reticulum. J Biol Chem 1998; 273:15030 - 15034
   PubMed Web of Science ®Google Scholar
• Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004; 343:417 - 433
   PubMed Web of Science ®Google Scholar
• Clarke S, Tamanoi F. Fighting cancer by disrupting C-terminal methylation of signaling proteins. J Clin Invest 2004; 113:513 - 515
   PubMed Web of Science ®Google Scholar
• Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002; 420:629 - 635
   PubMed Web of Science ®Google Scholar
• Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE 2004; 2004:13
   Google Scholar
• Matozaki T, Nakanishi H, Takai Y. Small G-protein networks: their crosstalk and signal cascades. Cell Signal 2000; 12:515 - 524
   PubMed Web of Science ®Google Scholar
• Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, et al. Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol 2006; 2:518 - 528
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295 - 308
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008; 15:1478 - 1492
   PubMed Web of Science ®Google Scholar
• Bergo MO, Gavino BJ, Hong C, Beigneux AP, McMahon M, Casey PJ, et al. Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf. J Clin Invest 2004; 113:539 - 550
   PubMed Web of Science ®Google Scholar
• Winter-Vann AM, Baron RA, Wong W, Dela Cruz J, York JD, Gooden DM, et al. A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells. Proc Natl Acad Sci USA 2005; 102:4336 - 4341
   PubMed Web of Science ®Google Scholar
• Wang M, Tan W, Zhou J, Leow J, Go M, Lee HS, et al. A small molecule inhibitor of isoprenylcysteine carboxymethyltransferase induces autophagic cell death in PC3 prostate cancer cells. J Biol Chem 2008; 283:18678 - 18684
   PubMed Web of Science ®Google Scholar
• Wahlstrom AM, Cutts BA, Liu M, Lindskog A, Karlsson C, Sjogren AK, et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 2008; 112:1357 - 1365
   PubMedGoogle Scholar
• Lu Q, Harrington EO, Hai CM, Newton J, Garber M, Hirase T, et al. Isoprenylcysteine carboxyl methyltransferase modulates endothelial monolayer permeability: involvement of RhoA carboxyl methylation. Circ Res 2004; 94:306 - 315
   PubMed Web of Science ®Google Scholar
• Backlund PS Jr. Post-translational processing of RhoA. Carboxyl methylation of the carboxyl-terminal prenylcysteine increases the half-life of Rhoa. J Biol Chem 1997; 272:33175 - 33180
   PubMed Web of Science ®Google Scholar
• Harrington EO, Newton J, Morin N, Rounds S. Barrier dysfunction and RhoA activation are blunted by homocysteine and adenosine in pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol 2004; 287:1091 - 1097
   Web of Science ®Google Scholar
• Michaelson D, Ali W, Chiu VK, Bergo M, Silletti J, Wright L, et al. Postprenylation CAAX processing Is required for proper localization of Ras but not Rho GTPases. Mol Biol Cell 2005;
   PubMed Web of Science ®Google Scholar
• Cushman I, Casey PJ. Role of isoprenylcysteine carboxylmethyltransferase-catalyzed methylation in Rho function and migration. J Biol Chem 2009; 284:27964 - 27973
   PubMedGoogle Scholar
• Papaharalambus C, Sajjad W, Syed A, Zhang C, Bergo MO, Alexander RW, et al. Tumor necrosis factor alpha stimulation of Rac1 activity. Role of isoprenylcysteine carboxylmethyltransferase. J Biol Chem 2005; 280:18790 - 18796
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, et al. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem 2008; 283:25150 - 25163
   PubMed Web of Science ®Google Scholar
• Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metast Rev 2009; 28:65 - 76
   PubMed Web of Science ®Google Scholar
• Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11:306 - 315
   PubMed Web of Science ®Google Scholar
• Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609 - 641
   PubMed Web of Science ®Google Scholar
• Bocan TM. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr Opin Investig Drugs 2002; 3:1312 - 1317
   PubMedGoogle Scholar
• Hoffman GR, Nassar N, Cerione RA. Structure of the Rho family GTP-binding protein Cdc42 in complex with the multifunctional regulator RhoGDI. Cell 2000; 100:345 - 356
   PubMed Web of Science ®Google Scholar
• Grizot S, Faure J, Fieschi F, Vignais PV, Dagher MC, Pebay-Peyroula E. Crystal structure of the Rac1-RhoGDI complex involved in nadph oxidase activation. Biochemistry 2001; 40:10007 - 10013
   PubMed Web of Science ®Google Scholar
• Rolli-Derkinderen M, Sauzeau V, Boyer L, Lemichez E, Baron C, Henrion D, et al. Phosphorylation of serine 188 protects RhoA from ubiquitin/proteasome-mediated degradation in vascular smooth muscle cells. Circ Res 2005; 96:1152 - 1160
   PubMed Web of Science ®Google Scholar
• Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, Fujioka H, et al. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 1991; 6:515 - 522
   PubMed Web of Science ®Google Scholar
• Mizuno T, Kaibuchi K, Yamamoto T, Kawamura M, Sakoda T, Fujioka H, et al. A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc Natl Acad Sci USA 1991; 88:6442 - 6446
   PubMed Web of Science ®Google Scholar